TrialInternational journal of clinical oncology2021

Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial.

Hiroji Uemura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.